159 related articles for article (PubMed ID: 31451252)
1. The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study.
Akita H; Takahashi H; Asukai K; Tomokuni A; Wada H; Marukawa S; Yamasaki T; Yanagimoto Y; Takahashi Y; Sugimura K; Yamamoto K; Nishimura J; Yasui M; Omori T; Miyata H; Ochi A; Kagawa A; Soh Y; Taniguchi Y; Ohue M; Yano M; Sakon M
Clin Nutr ESPEN; 2019 Oct; 33():148-153. PubMed ID: 31451252
[TBL] [Abstract][Full Text] [Related]
2. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer.
Barber MD; Ross JA; Voss AC; Tisdale MJ; Fearon KC
Br J Cancer; 1999 Sep; 81(1):80-6. PubMed ID: 10487616
[TBL] [Abstract][Full Text] [Related]
3. Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial.
Read JA; Beale PJ; Volker DH; Smith N; Childs A; Clarke SJ
Support Care Cancer; 2007 Mar; 15(3):301-7. PubMed ID: 17021855
[TBL] [Abstract][Full Text] [Related]
4. Randomized clinical trial comparing standard diet with perioperative oral immunonutrition in total gastrectomy for gastric cancer.
Ida S; Hiki N; Cho H; Sakamaki K; Ito S; Fujitani K; Takiguchi N; Kawashima Y; Nishikawa K; Sasako M; Aoyama T; Honda M; Sato T; Nunobe S; Yoshikawa T
Br J Surg; 2017 Mar; 104(4):377-383. PubMed ID: 28072447
[TBL] [Abstract][Full Text] [Related]
5. Eicosapentaenoic acid in cancer improves body composition and modulates metabolism.
Pappalardo G; Almeida A; Ravasco P
Nutrition; 2015 Apr; 31(4):549-55. PubMed ID: 25770317
[TBL] [Abstract][Full Text] [Related]
6. A disease-specific enteral nutrition formula improves nutritional status and functional performance in patients with head and neck and esophageal cancer undergoing chemoradiotherapy: results of a randomized, controlled, multicenter trial.
Fietkau R; Lewitzki V; Kuhnt T; Hölscher T; Hess CF; Berger B; Wiegel T; Rödel C; Niewald M; Hermann RM; Lubgan D
Cancer; 2013 Sep; 119(18):3343-53. PubMed ID: 23765693
[TBL] [Abstract][Full Text] [Related]
7. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial.
Sawada T; Tsubata H; Hashimoto N; Takabe M; Miyata T; Aoki K; Yamashita S; Oishi S; Osue T; Yokoi K; Tsukishiro Y; Onishi T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H; Yokoyama M
Cardiovasc Diabetol; 2016 Aug; 15(1):121. PubMed ID: 27565734
[TBL] [Abstract][Full Text] [Related]
8. Effect of eicosapentaenoic acid on prevention of lean body mass depletion in patients with exacerbation of chronic obstructive pulmonary disease: A prospective randomized controlled trial.
Ogasawara T; Marui S; Miura E; Sugiura M; Matsuyama W; Aoshima Y; Kasamatsu N; Ogiku M; Ikematsu Y
Clin Nutr ESPEN; 2018 Dec; 28():67-73. PubMed ID: 30390895
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy evaluation of an oral powder supplement enriched with eicosapentaenoic acid in cancer patients].
Gómez-Candela C; Villarino Sanz M; Horrisberger A; Loria Kohen V; Bermejo LM; Zamora Auñón P
Nutr Hosp; 2011; 26(6):1385-93. PubMed ID: 22411387
[TBL] [Abstract][Full Text] [Related]
10. Effect of eicosapentaenoic acids-rich fish oil supplementation on motor nerve function after eccentric contractions.
Ochi E; Tsuchiya Y; Yanagimoto K
J Int Soc Sports Nutr; 2017; 14():23. PubMed ID: 28717347
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy.
Akahori T; Sho M; Kinoshita S; Nagai M; Nishiwada S; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Nakajima Y
World J Surg; 2015 Dec; 39(12):2975-82. PubMed ID: 26296840
[TBL] [Abstract][Full Text] [Related]
12. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial.
Sánchez-Lara K; Turcott JG; Juárez-Hernández E; Nuñez-Valencia C; Villanueva G; Guevara P; De la Torre-Vallejo M; Mohar A; Arrieta O
Clin Nutr; 2014 Dec; 33(6):1017-23. PubMed ID: 24746976
[TBL] [Abstract][Full Text] [Related]
13. Effect of rosuvastatin and eicosapentaenoic acid on neoatherosclerosis: the LINK-IT Trial.
Kuroda K; Otake H; Shinohara M; Kuroda M; Tsuda S; Toba T; Nagano Y; Toh R; Ishida T; Shinke T; Hirata KI
EuroIntervention; 2019 Dec; 15(12):e1099-e1106. PubMed ID: 31334703
[TBL] [Abstract][Full Text] [Related]
14. Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study.
Nosaka K; Miyoshi T; Iwamoto M; Kajiya M; Okawa K; Tsukuda S; Yokohama F; Sogo M; Nishibe T; Matsuo N; Hirohata S; Ito H; Doi M
Int J Cardiol; 2017 Feb; 228():173-179. PubMed ID: 27865182
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Preoperative Enteral Nutrition Enriched with Eicosapentaenoic Acid on Postoperative Hypercytokinemia after Pancreatoduodenectomy: The Results of a Double-Blinded Randomized Controlled Trial.
Ashida R; Okamura Y; Wakabayashi-Nakao K; Mizuno T; Aoki S; Uesaka K
Dig Surg; 2019; 36(4):348-356. PubMed ID: 29886499
[TBL] [Abstract][Full Text] [Related]
16. Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review.
Elia M; Van Bokhorst-de van der Schueren MA; Garvey J; Goedhart A; Lundholm K; Nitenberg G; Stratton RJ
Int J Oncol; 2006 Jan; 28(1):5-23. PubMed ID: 16327975
[TBL] [Abstract][Full Text] [Related]
17. Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial.
Ryan AM; Reynolds JV; Healy L; Byrne M; Moore J; Brannelly N; McHugh A; McCormack D; Flood P
Ann Surg; 2009 Mar; 249(3):355-63. PubMed ID: 19247018
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
Akita H; Takahashi H; Ohigashi H; Tomokuni A; Kobayashi S; Sugimura K; Miyoshi N; Moon JH; Yasui M; Omori T; Miyata H; Ohue M; Fujiwara Y; Yano M; Ishikawa O; Sakon M
Eur J Surg Oncol; 2017 Jun; 43(6):1061-1067. PubMed ID: 28389044
[TBL] [Abstract][Full Text] [Related]
19. Exercise during and after neoadjuvant rectal cancer treatment (the EXERT trial): study protocol for a randomized controlled trial.
Morielli AR; Usmani N; Boulé NG; Severin D; Tankel K; Nijjar T; Joseph K; Fairchild A; Courneya KS
Trials; 2018 Jan; 19(1):35. PubMed ID: 29329555
[TBL] [Abstract][Full Text] [Related]
20. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids.
Moses AW; Slater C; Preston T; Barber MD; Fearon KC
Br J Cancer; 2004 Mar; 90(5):996-1002. PubMed ID: 14997196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
